We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Primary Endpoint

News List

Teva, Xenon Announce Phase II Study of Topical TV-45070 Did Not Meet Primary Endpoint americanpharmaceuticalreview
June 28, 2017
Teva Pharmaceutical and Xenon Pharmaceuticals announce top-line results in a Phase II study of topical TV-45070 in patients with post-herpetic neuralgia (PHN) did not meet the primary endpoint of a statistically significant change in pain from baseline to
Teva and Active Biotech Announce Concerto Trial of Laquinimod did not Meet Primary Endpoint americanpharmaceuticalreview
May 09, 2017
Teva Pharmaceutical Industries and Active Biotech announced results from the Concerto trial in patients with relapsing-remitting multiple sclerosis (RRMS).

Previous page 1 2 Next page